This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Akero Therapeutics ( NASDAQ:AKRO ) , Apartment Inv & Mgmt ( NYSE:AIV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. TD Cowen analyst Ritu Baral initiated coverage on Akero Therapeutics, Inc.
Wave ( WVE ) Q2 Revenue Drops 56%
Wave Life Sciences ( NASDAQ:WVE ) , a clinical-stage biotechnology company focused on RNA-based medicines, reported second-quarter earnings on July 30, 2025, for the period ending June 30. The company missed Wall Street expectations by a wide margin, delivering revenue of $8.7 million for Q2 2025 ...
Wave Life Sciences ( WVE ) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.90% and -31.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients. multi-dosing is complete in first cohort ( 200 mg ) and single dosing is complete in second ...
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Accenture ( NYSE:ACN ) , Allarity Therapeutics ( NASDAQ:ALLR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ascendiant Capital analyst Edward Woo initiated coverage on Alarum Technologies Ltd.
Illumina ( ILMN ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
CAMBRIDGE, Mass., July 23, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m.
CRISPR Therapeutics ( CRSP ) Moves 9.6% Higher: Will This Strength Last?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism ( INHBE ) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions - WAVE Life Sciences ( NASDAQ:WVE )
Presentation to highlight WVE-007 ( INHBE GalNAc-siRNA ) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism ( INHBE ) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
Presentation to highlight WVE-007 ( INHBE GalNAc-siRNA ) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation ...
Wave Life Sciences ( WVE ) Reports Q1 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.41% and 34.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Geron ( GERN ) Reports Q1 Loss, Lags Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of 25% and 18.75%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics ( MYGN ) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 2.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Wave Life Sciences ( WVE ) to Report a Decline in Earnings: What to Look Out for
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
CAMBRIDGE, Mass., May 01, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m.
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics
Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics are part of the Zacks top Analyst ...
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Wave Life Sciences ( WVE ) Stock Jumps 6.1%: Will It Continue to Soar?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - WAVE Life Sciences ( NASDAQ:WVE )
Wave Life's WVE-N531 met all Phase 2 goals, showing exon skipping, dystrophin restoration. The therapy showed a 28.6% muscle fibrosis reduction, a 50% CK decline, and decreased IL-6/MCP-1, supporting its potential for DMD treatment Feel unsure about the market's next move?
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531 - WAVE Life Sciences ( NASDAQ:WVE )
Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks. additional functional benefits observed in other outcome measures including ...
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Adma Biologics ( ADMA ) Surges 10.2%: Is This an Indication of Further Gains?
Adma Biologics (ADMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025. enrollment complete in first single dose cohort ...
Seer, Inc. ( SEER ) Reports Q4 Loss, Tops Revenue Estimates
Seer (SEER) delivered earnings and revenue surprises of 15% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Foghorn Therapeutics Inc. ( FHTX ) Report Negative Q4 Earnings? What You Should Know
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Infinity ( NYSE:INR ) , Insmed ( NASDAQ:INSM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Roger Song initiated coverage on Wave Life Sciences Ltd.
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
CAMBRIDGE, Mass., Feb. 25, 2025 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m.
SpringWorks Therapeutics ( SWTX ) Reports Q4 Loss, Tops Revenue Estimates
SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -44.44% and 2.52%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 ( siRNA Targeting INHBE ) in Obesity - WAVE Life Sciences ( NASDAQ:WVE )
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - WAVE Life Sciences ( NASDAQ:WVE )
CAMBRIDGE, Mass., Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. WVE, a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is ...
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive ...
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Shares of the international gene therapy developer uniQure ( NASDAQ: QURE ) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration ( FDA ) and the company's Huntington's disease candidate.During the first 12 days of December, shares of uniQure ...
Wave Life Sciences to Present at Upcoming Investor Conferences - WAVE Life Sciences ( NASDAQ:WVE )
CAMBRIDGE, Mass., Nov. 26, 2024 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. WVE, a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is ...
Wave Life Sciences to Present at Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- Wave Life Sciences Ltd. ( Nasdaq: WVE ) , a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive ...
Wave Life Sciences ( WVE ) Reports Q3 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -67.86% and 149.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Novavax to Report Q3 Earnings: Here's What to Expect
On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA to remove the clinical hold on its two vaccine programs.
Wave Life Sciences ( WVE ) Expected to Beat Earnings Estimates: Should You Buy?
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
WVE-007 ( INHBE GalNAc-siRNA for obesity ) is on track to initiate a clinical trial in 1Q 2025. new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of ...
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences ( WVE ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Wave Life Sciences (WVE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
EQS-News: BB Biotech: Strategic reallocation of portfolio assets progressing
BB Biotech: Strategic reallocation of portfolio assets progressing Portfolio of BB Biotech AG as at September 30, 2024 A key event during the period under review was the US Federal Reserve's decision in September to lower interest rates by 50 bps, marking its first rate cut in four years.
1 Brand-New Big Reason to Buy This Biotech Stock Right Now
This stock currently has a good balance of risk and potential rewards.
What Makes Wave Life Sciences ( WVE ) a Strong Momentum Stock: Buy Now?
Does Wave Life Sciences (WVE) have what it takes to be a top stock pick for momentum investors? Let's find out.
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.
Wave Life Sciences ( WVE ) Moves 74.1% Higher: Will This Strength Last?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Cisco Systems ( NASDAQ:CSCO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird analyst David Manthey upgraded the rating for W.W. Grainger, Inc.
Looking At WAVE Life Sciences's Recent Unusual Options Activity - WAVE Life Sciences ( NASDAQ:WVE )
Whales with a lot of money to spend have taken a noticeably bullish stance on WAVE Life Sciences. Looking at options history for WAVE Life Sciences WVE we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish ...
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans - WAVE Life Sciences ( NASDAQ:WVE )
Wave Life Sciences Ltd. WVE stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency ( AATD ) , an inherited genetic disorder that causes low levels of a protein ( AAT ) ...
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday - United Airlines Holdings ( NASDAQ:UAL )
U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Wednesday. Shares of United Airlines Holdings, Inc. UAL rose sharply during Tuesday's session following better-than-expected quarterly earnings.
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE program for obesity Event will highlight WVE-006 for AATD and Wave's rapidly advancing, wholly ...
